Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 7, 2000, Pages 1737-1744

  Autieri, Michael V ^a   Carbone, Christopher ^a   Mu, Anbin ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allograft inflammatory factor 1; Balloon angioplasty; Cytokines; Transplant arteriopathy; Vascular smooth muscle cells

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; CALCIUM BINDING PROTEIN; CELL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTERY INJURY; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SMOOTH MUSCLE FIBER; SWINE; TISSUE DISTRIBUTION; VASCULAR SMOOTH MUSCLE;

EID: 0033912849     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.7.1737     Document Type: Article

References (38)

1. Ip JH, Fuster V, Badimon L, Badimon J, Taubman M, Chesebro J. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15:1667-1687.
2. Miller LW. Allograft vascular disease, a disease not limited to hearts. J Heart Lung Transplant. 1992;11:932-936.
3. Brodsky FM, Guagliardi L. The cell biology of antigen processing and presentation. Annu Rev Immunol. 1991;9:707-744.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.
6. Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1380.
7. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;6:369-375.
8. Ventura HO, Mehra MR, Smart FW. Cardiac allograft vasculopathy: current concepts. Am Heart J. 1995;129:791-798.
9. Libby P, Salomon R, Payne D, Schoen F, Pober J. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 1989;21:3677-3684.
10. Gregory C, Huie P, Billingham M, Morris R. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Transplantation. 1993;55:1409-1418.
11. Epstein SE, Speir E, Unger EF, Guzman RJ, Finkel T. The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol. 1994;23:1278-1288.
12. Zhu NL, Wu L, Liu PX, Gordon EM, Anderson WF, Starnes VA, Hall FL. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation. 1997;96:628-635.
13. Utans U, Arceci R, Yamashita Y, Russell M. Cloning and characterization of allograft Inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest. 1995;95:2954-2960.
14. Autieri MV. cDNA cloning of human allograft inflammatory factor-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. Biochem Biophys Res Commun. 1996;228:29-37.
15. Metha D, Angelini GD, Bryan AJ. Experimental models of accelerated atherosclerosis syndromes. Int J Cardiol. 1996;56:235-257.
16. Autieri MV, Carbone C. 14-3-3γ interacts with and is phosphorylated by multiple PKC isoforms in PDGF-stimulated human vascular smooth muscle cells. DNA Cell Biol. 1999;18:555-564.
17. Mennander A, Tiisala S, Halttunen J, Yilmaz S, Paavonen T, Hayry P. Chronic rejection in rat aortic allografts: an experimental model for transplant arteriosclerosis. Arterioscler Thromb. 1991;11:671-680.
18. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Transplantation. 1993;55:1409-1418.
19. Isik FF, McDonald TO, Ferguson M, Yamanaka E, Gordon D. Transplant arteriosclerosis in a rat aortic model. Am J Pathol. 1992;141:1139-1149.
20. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
21. Schwartz R, Huber L, Murphy J. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
22. Indolfi C, Esposito G, DiLorenzo E, Rapacciuolo A, Feliciello A, Porcellini A, Avedimento VE, Condorelli M, Chiariello M. Smooth muscle cell proliferation is proportional to the degrees of balloon injury in a rat model of angioplasty. Circulation. 1995;92:1230-1235.
23. Scott N, Cipolla G, Ross C, Dunn B, Martin F, Simonet L, Wilcox J. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 1996;93:2178-2187.
24. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
25. Demaeyer E, Demayer-Guignard J. Interferons and Other Regulatory Cytokines. New York, NY: John Wiley & Sons Inc; 1988.
26. Russell ME. Macrophages and transplant arteriosclerosis: known and novel molecules J Heart Lung Transplant. 1995;14:S111-S115.
27. Wang W, Chen HJ, Giedd KN, Schwartz A, Cannon PJ, Rabbani LE. T-cell lymphokines, interleukin-4, and gamma interferon, modulate the induction of vascular smooth muscle tissue plasminogen activator and migration by serum and platelet-derived growth factor. Circ Res. 1995; 77:1095-1106.
28. Rolfe BE, Campbell JH, Smith NJ, Cheong MW, Campbell GR. T lymphocytes affect smooth muscle cell phenotype and proliferation. Arterioscler Thromb Vasc Biol. 1995;15:1204-1210.
29. Means A. Calcium, calmodulin, and cell cycle regulation. FEBS Lett. 1994;347:1-4.
30. Pauly R, Bilato C, Sollott S, Monticone R, Kelly P, Lakatta E, Crow M. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation. 1995;91: 1107-1115.
31. 2+ channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci U S A, 1989;86:2366-2392.
32. Rasmussen C, Means AR. Calmodulin is required for cell-cycle progression during G1 and mitosis. EMBO J. 1989;8:73-82.
33. Enslen H, Tokimitsu H, Stork P, Davis R, Soderling T. Regulation of mitogen-activated protein kinases by a calcium/calmodulin-independent protein kinase cascade. Proc Natl Acad Sci U S A. 1996 93;10803-10808.
34. Whitworth HB, Roubin GS. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1986;8:1271-1276.
35. Hoberg E. The effects of calcium antagonists after PTCA. Eur Heart J. 1995;16(Suppl 11):9-12.
36. Jackson CL, Bush RC, Bowyer DE. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis. 1988;69:115-122.
37. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med. 1993;328:164-170.
38. Schwartz RS. Neointima and arterial injury: dogs, rats, pigs, and more. Lab Invest. 1994;71:789-791.